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Objective: The gold standard for measuring blood-retinal barrier permeability is the Evans 
blue assay. However, this technique has limitations in vivo, including non-specific tissue 
binding and toxicity. This study describes a non-toxic, high throughput and cost effective 
alternative technique that minimizes animal usage. Methods: Sodium fluorescein fundus 
angiography was performed in non- and diabetic Brown Norway rats on days 0, 7, 14, 21 and 
28. Sodium fluorescein intensity in the retinal interstitium and a main retinal vessel were 
measured over time. The intensity gradients were used to quantify retinal vascular 
permeability. Post study eyes were fixed, dissected and stained (isolectin B4) to measure 
required parameters for permeability quantification including: Total vessel length per retinal 
volume, radius and thickness. Results: In the non-diabetic cohort retinal permeability 
remained constant over the 28-day study period. However, in the diabetic cohort there was a 
significant and progressive increase in retinal permeability from day 14 to 28 (p<0.01, p<0.001, 
p<0.0001). Conclusions: This novel imaging methodology in combination with mathematical 
quantification allows retinal permeability to be non-invasively and accurately measured at 
multiple time points in the same animal. In addition, this technique is a non-toxic, rapid, 
sensitive and cost-effective alternative to the Evans blue assay. 
 
Keywords: Retina; vessel; fundus fluorescein angiography; permeability; Fick's Law; 








EC   Endothelial cell 
BBB   Blood-brain barrier 
BRB   Blood-retinal barrier 
EB   Evans blue 
FFA   Fundus fluorescein angiography 
STZ   Streptozotocin 
i.p.   Intraperitoneal 
GLUT2 Glucose transporter 2 
Na-Fl   Sodium fluorescein salt 
PBS   Phosphate buffered saline 
avi   Audio video interleave 
𝑃𝑠   Solute permeability to solute s e.g. Fluorescein: 𝑃𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑖𝑛 
OCT   Optical coherence tomography 
RPE   Retinal pigmented epithelium 












Selective permeable barriers are vital for organ function and homeostasis. Such barriers 
include the EC barrier of blood vessels, the BBB[1], the BRB[2], the blood-spinal cord barrier[3] 
and the blood-placental barrier[4]. Selective transport of micromolecular substances across 
these barriers occurs under physiological conditions but they are relatively impermeable to 
macromolecules such as albumin [5]. EB dye has a high affinity for albumin[6] and has a poor 
ability to cross selective permeable barriers under normal circumstances and remains 
predominantly within the blood circulation[5]. When diseases such as diabetic retinopathy[7], 
sepsis[8], capillary leak syndrome[9] or cancer[10] result in disruption of these barriers there 
is an increase in vascular permeability and dyes such as EB may extravasate from the 
circulation into surrounding tissues. Leak of dyes such as this across blood vessels or the 
BBB/BRB can signify damage and breakdown of the barrier via trauma or cytokine release. 
Accumulation of EB dye can be extracted from stained tissues and quantified by 
spectrophotometry[11, 12]. EB is extensively used to estimate changes in vascular 
permeability in a number of models including in stroke[13], cerebral ischaemia[11], skin[14] 
(often referred to as a Miles assay (Huang et al 2016), endothelial damage caused by 
trauma[15] and the breast cancer brain metastasis model[10]. EB has also been used to 
measure breakdown in the blood-spinal cord barrier[16] [17], and the BRB [18] [19]. 
 The EB assay is rapid, sensitive and has become a widely used method for estimating 
barrier integrity and vascular permeability.  However, this methodology has a number of 
significant assumptions associated with its use which can lead to significant over-simplification 
of the research findings if unaccounted for. These include: (i) the contribution of convective 
flux of albumin (and dye bound albumin) to the total flux varying from minimal to highly 
significantly dependent on haemodynamic parameters rather than barrier properties (ii) a 
substantive percent of free dye present in the animal following administration, resulting in flux 
being highly blood flow dependent rather than barrier dependent[1, 20] (iii) lack of specific 
binding to albumin, (iv) injection of dye dissolved in physiological solutions affects the 
structure of the dye, (v) EB binds albumin when it is in the tissues, (vi) change in tissue 
clearance can account for the changes (vii) problems with spectroscopic methods that have 
been used to estimate the amount of dye, and (viii) in vivo toxicity[20, 21]. These issues have 
been highlighted many times and are extensively discussed elsewhere. 
 This study describes a non-toxic and high throughput alternative technique to the EB 
assay in the retina. In combination with the Micron IV retinal imaging microscope system 
(Phoenix Research Systems, CA), we have used FFA and a novel post imaging analysis 
methodology described below. This technique can be carried out in less than 15 minutes, is 
minimally invasive and can be repeated in animals, resulting in a reduction of the number of 
animals required when compared to the EB assay, which takes 2-3 hours to carry out per 
animal and requires multiple cohorts of animals per time point. In addition, we have estimated 
that our novel methodology is significantly more efficient than the EB assay to perform. 
 
Materials and Methods 
Animals ethics: Experimental animals were treated in accordance with the ARVO Statement 
for the Use of Animals in Ophthalmic and Vision Research, and under a UK Home Office 
licence (PPL 30/3184), at the University of Nottingham Biological Services Unit.  
Gender selection: Male Brown Norway rats, which are more susceptible to STZ-induced 
diabetes, (250-300g, Envigo, U.S.A) were included in this study. 
STZ dose and route of administration: A total of 40 male Brown Norway rats were weighed 
and given a single intraperitoneal (i.p.) injection of STZ (Sigma–Aldrich, MO, U.S.A.). An 
additional 14 control rats were administered 300 μl saline i.p. 
Fast or non-fasted prior to STZ dosing: Fasting can be used to minimize competition between 
STZ and glucose for low affinity GLUT2 transporters on β cells. In the period following STZ 
dosing the animals enter a hypoglycaemic state and begin to show signs of sudden weight 
loss, polyuria and dehydration. In our initial pilot study, animals were fasted overnight, prior to 
dosing in the morning, but their weights dropped dramatically during that period and this had 
a subsequent effect on weight loss in the proceeding study, exceeding a 20% weight loss 
moderate severity threshold. Therefore, in the subsequent study we did not fast prior to dosing. 
We ran the risk of the animals not becoming diabetic (~10% of cases) but this allowed the 
animals to feed, retain or increase their weights prior to dosing and avoid the subsequent 
decline in health and weight otherwise observed. Animals with weights exceeding 300g 
tolerated the 50mg/kg STZ dose and maintained weights throughout the study or until the 
point of insulin supplementation.  
Sucrose enrichment: In addition to water, a 15% (w/v) sucrose solution was made available in 
a separate drinking bottle to alleviate the initial hypoglycaemic spike following STZ induction. 
The volume of sucrose intake was monitored over a 72-hour period.  
Insulin supplementation: Current blood glucose control in diabetic rodent models focuses on 
maintaining the diabetic animal in a state of moderate hyperglycaemia, with normal weight 
gain in the absence of severe ketonuria. This state can be achieved by once-daily injections 
of titrated insulin doses or by implantation of a continuous release insulin pellet. To reduce 
animal stress by repeated injections we subcutaneously implanted one third of a single insulin 
pellet (LinShin, Canada). The 7-mm long implant has a diameter of 2 mm and is designed to 
facilitate handling and insertion. Upon implantation, gradual erosion of the implant starts at 
once, and the effect of released insulin on the blood glucose level can be detected in <1h. 
Unlike injectable insulin, the implant releases a set basal dose of insulin every hour. Therefore, 
an animal given an optimal implant dose should show no glucosuria and ketonuria, which are 
both difficult to prevent by daily insulin injections, due to the action of the insulin lasting only 
part of the 24-hour cycle. 
Blood glucose measurement: On days 0, 4 and prior to sacrifice (day 28) blood glucose levels 
were tested using a sample of blood taken from the tail vein and an Accuchek blood glucose 
monitor. Rats with blood glucose levels of >15 mmol/l and above were deemed 
hyperglycaemic. STZ-injected rats that did not become hyperglycaemic on day 4 were re-
injected with STZ the following morning and subsequently evaluated for diabetes, as outlined 
above. 
Optimisation of anaesthetic knockdown: Due to the severity of the diabetic model and in 
combination with injectable anaesthetics, gaseous anaesthesia (halothane) was trialled. 
However, this had constraints. Firstly, the small animal gaseous mask sat just underneath the 
eye making it very difficult to align the retinal microscope with the eye without dislodging the 
gaseous mask and risking the animal becoming lucid. Secondly, gaseous anaesthesia was 
not sufficient to prevent the eye from responding to the light source, blinking and rolling during 
imaging, without giving a high percentage of halothane. Injectable anaesthetic removed the 
cumbersome equipment required for gaseous knockdown, the control of multiple flow meters 
and ultimately stabilised the animal to prevent the eye from moving during FFA. We therefore 
used an injectable anaesthetic regimen combining ketamine hydrochloride, 37.5 mg/kg 
(Zoetis) and medetomidine hydrochloride, 0.25 mg/kg (Produlab Pharma BV) i.p. 
Optimisation of Na-Fl dose and volume: Na-Fl (M.W. 376.27) was prepared in sterile water 
and 0.2m filtered 0.1, 10, 100 mg/ml dilutions were prepared and stored at room temperature 
and away from direct light until required. Intraperitoneal injections were administered in a non-
injected lower quadrant of the abdomen whilst the anaesthetised rat was on the imaging cradle 
and the retina of the right eye had been previously located and aligned using the Micron IV. 
This was achieved by raising the right back leg, maintaining retinal alignment by minimal 
animal movement. The retinal imaging software was set to record prior to injection and 
continued to record until the dye had reached a saturation level in the retina (~ 3 min). 
Optimisation of Na-Fl route of administration: Two routes of administration, intraperitoneal and 
intravenous were tested with all three doses of Na-Fl. The tail was pre-warmed in a beaker of 
warm water (30-35 C) to dilate the blood vessels and an intravenous injection was 
administered via the lateral tail vein. This method was more technically demanding and 
resulted in a sudden saturation of the retinal vasculature in approximately 30s. In comparison 
the i.p. route was simpler to administer and gave more gradual leakage of the dye into the 
retinal vasculature, over a period of approximately 3 min.  
Animals were anaesthetised as previously described and transferred to an image cradle fitted 
with a heat mat. Viscotears was applied to the cornea of both eyes to prevent dehydration and 
whiskers were placed out of the field of view using a cotton tip. The Micron IV was advanced 
towards the cornea and the optic nerve was centred in the field of view, altering the brightness 
and focus to achieve a crisp image of the main retinal vessels. Once the eye was correctly 
aligned bright field fundus images of the retina were captured to check for any ocular 
abnormalities. The green filter was selected and a 3 min video footage of the retina was 
recorded at 15 frames per second. Animals then received a single 250 l i.p. injection of Na-
Fl. This was repeated on days 7, 14, 21 and 28 aligning the eye in the same position as 
captured on day 0. Development of cataracts with resultant blurring of posterior segment view 
meant that some eyes (n=2) were excluded from the consecutive FFA. Due to the rapid uptake 
and delayed elimination of Na-Fl from the animal’s circulatory system only one eye could be 
imaged per session.  
FFA analysis: Angiograms were imported as avi files into Fiji software[22] and mean 
fluorescence intensity was measured in a major retinal vessel and nearby tissue (which 
includes unresolved capillaries) every 200 frames up to 2400 frames. An initial time course 
was plotted and only the region where there was detectable tissue fluorescence but no major 
vessel saturation was used for analysis. 
Immunofluorescence: Post euthanasia, on day 28, eyes were enucleated and immediately 
fixed in 4% PFA for 30 min. Retinae were excised from the scleral/choroidal cup and stained 
with an endothelial cell specific marker, isolectin B4 (lectin from Bandeiraea simplicifolia 
conjugated to biotin) followed by Alexa Fluor 488-streptavidin. Whole-mounted retinae were 
imaged using confocal microscopy (Leica TCS SPE) to generate z stacks, and allow for 
analyses of vascular structural parameters across the superficial and deep plexuses. Length 
per volume and mean radius were measured using Fiji software[22] by manually drawing 
along all vessels using the freehand line tool. The distance between the upper and lower 
plexus was taken as the vascular retinal thickness.  
Statistical Analysis: Unless otherwise stated, all data are shown as meanSEM. All data, and 
graphs were formulated with Microsoft Excel (Microsoft Office Software), GraphPad Prism 
v7/8 (GraphPad Software Inc., CA, U.S.A.), Fiji and Imaris. Vascular spacing statistical 
analysis was calculated using a one-way ANOVA with Bonferroni's correction and 28-day 
permeability analysis was calculated using a two-way ANOVA with Bonferroni's correction. All 




To quantify the effective solute permeability (𝑃𝑠) for the vascular wall the parameter derivation 
in Appendix 1 was used, which is directly comparable to previous derivations from single 
capillaries[23]. To enable this calculation to take place the fluorescence intensity was 
measured in one of the major retinal blood vessels, and in a box outside the major retinal 
vessel containing no visibly distinct vessels (i.e. no vessels larger than approximately 20µm 
in diameter, Figure 2A). The permeability to fluorescein (Pfluorescein) was estimated as described 
in Appendix 1 using FFA (Figure 2B). The calculations make the assumptions that the surface 
area available for exchange is the same in the diabetic animal as the control.  
 To determine these parameters tissue was stained to quantify the retinal vasculature. 
The retina has two clear plexuses (Figure 3A), one at the surface and one within the retinal 
layer. The vascular length (Figure 3B) and radius (Figure 3C) was calculated. There was no 
significant difference between the mean radius, the distance between the two plexuses (Figure 
3D), nor the length of vessel per confocal volume. 
  We therefore calculated the permeability using cohort parameters and assuming that 
the surface area was unchanged throughout for each cohort. Figure 4A shows that while 
permeability remained constant in non-diabetic animals, there was a significant and 
progressive increase in permeability in diabetic animals. 
 To determine whether permeability could be linked the data for all three diabetic and 
six controls over 28 days is shown (Figure 4B). These results show that the increase in 
permeability is progressive and that paired (linked) analysis can be used to determine a 
progressive increase in permeability with diabetic duration, allowing for a substantial reduction 
in number of animals per group as well as a reduction in overall numbers.  
 
Discussion 
These data show that the STZ model of diabetes (with insulin supplementation) in rats induces 
increased vascular permeability in the retina. This has been shown before via other methods 
[19] [18] and in other neuronal tissues, indicating a systemic response [19]. However, of note 
is that the permeability increases early including a trend at day 7, reaching significance by day 
14, i.e. in early stages prior to gross vascular remodelling, as observed by measuring between 
the plexuses in the retina where there was no significant thickening (e.g. by oedema) of this 
layer. The FFA approach shown is practical, using repeated measures over a time course i.e. 
for therapeutic intervention, and could if desired be used in combination with other techniques 
such as OCT.  
 Leakage (increased solute flux from blood to tissue) can be caused by enhanced 
vascular permeability, increased driving force for flux (e.g. enhanced concentration gradient), 
increased surface area, or haemodynamic changes driving convective flux of solute. In the 
eye, homeostasis of the retina is maintained by the low permeability to proteins and water of 
the BRB. The outer BRB comprised of tight junctions between the RPE cells separates the 
choroid from the neuronal retina, and recent evidence indicates that it is also broken down in 
diabetes and contributes to retinal and macular oedema [19]. Evidence presented here 
confirms that the inner BRB, formed of the retinal vascular wall, becomes more permeable in 
this rat model of diabetes, contributing to the development of DR.  
 The current gold standard model of permeability measurement in the eye is the EB 
assay developed by Xu et al [18]. The EB assay can only be performed once per animal and 
therefore cannot be paired; hence, to be able to determine changes in permeability that 
develop over a four-week period, would require eight animals per group at three separate time 
points each (i.e. for three groups – control, diabetic, and diabetic+treatment) or a total of 72 
animals.  Eight animals per group are required because the measurements require the means 
of each group to be compared at each time point using a one-way analysis of variance, with 
post hoc analysis of each group resulting in 12 degrees of freedom (n=1 animals x n=1 groups 
= 6 x 2). In the methodology described here, the number per group can be reduced to a 
minimum of 3 because a two-way analysis of variance with a paired analysis is used resulting 
in the same 12 degrees of freedom (3 time points, n=1 groups, n=1 animals).  This results in 
a reduction in numbers of animals to 9 in total. Thus, the current methodology could reduce 
the animal numbers required to determine whether an intervention reduces retinal permeability 
by 8-fold which can be inferred as an increase in methodological sensitivity.  
 The retina permits non-invasive and direct in vivo visualisation of neuronal tissue and 
vasculature. Retinal imaging is an important diagnostic tool in ophthalmic disease and 
changes in retinal vasculature are used to determine the severity of systemic disease. Imaging 
can be undertaken with and without contrast agents. Na-Fl has been given intravenously since 
the mid 1900s to temporarily highlight retinal vessels and thus improving in vivo assessment 
of the retinal circulation and BRB integrity [24, 25]. Currently Na-Fl is administered as a topical 
clinical tool for a host of conditions including diabetes[26], glaucoma[25], vascular 
occlusions[27], neovascularisation[28] and inflammatory disorders [29]. With the 
advancement in wide-field fluorescein angiography subtle changes in the peripheral BRB 
disruption can be detected [30]. The principal of FFA is a series of collated images over time 
to demonstrate choroidal, arterial and venous filling, and clearance. Images are then visually 
examined to identify non-perfused areas or retained fluorescence that may indicate vascular 
compromise as indicated by fluorescein leakage. However intermittent timing and inaccurate 
timing limits the analysis of fluorescein images to a qualitative assessment. Vascular 
measurements that have been taken to date largely quantify the time it takes for Na-Fl to 
emerge in particular regions. Whilst useful, this does not provide information on the extent of 
change in the barrier function of the vasculature in any given location.  
 More recently, Hipwell et al have designed a method to analyse an entire fluorescein 
angiogram[31]. However, the analysis was limited to identifying the time to reach maximal 
fluorescence. Following on from this Hui et al and colleagues have outlined a quantitative 
spatial and temporal analysis of fluorescein angiography dynamics in a rodent model[32]. 
Therefore, the sensitivity is also limited to detect subtle changes such as differentiating 
vascular leakage from angiogenesis. However, video angiography could facilitate the 
quantitative analysis of more subtle differences in filling and leakage that occur in disease, for 
example early DR.  
 
Permeability Quantification 
Often permeability measurements determine solute flux, clearance or other parameters. When 
dealing with vasculopathies (e.g. diabetic) this can be important as individual exchange 
vessels can become more permeable, but the wider tissue could receive less molecules, for 
example due to fewer vessels. It is clear from EQ. 17 that the FFA technique is sensitive to 
the difference in the tissue and vessel intensity components; however, this is non-linear to the 
permeability so the ratio < 𝐼𝑉1 >/< 𝐼𝑉2 > or derivatives can only be used phenomologically to 
determine true permeability changes (i.e. changes in the barrier function of the vessel wall). 
In this STZ rodent model of diabetes there were no significant differences for the vessel radius 
or exchange length but the result is sensitive to these parameters and our vascular 
assessment was not on the imaged volume but a similar area on the retina. We expect that if 
there was a wider understanding of the contextual vascular structure, particularly between 
animals, or we could use the specific vessels used to measure 𝑃𝑠, then it would tighten the 
point variation. 
 The 𝑃𝑠 measured here is the effective 𝑃𝑠 meaning that we have not taken into account 
capillary net pressure. The net pressure is the sum of the hydrostatic pressure out of, and the 
oncotic pressure into, the vessel. It is not currently possible to measure the pressure in the 
capillaries in the retina non-invasively, which can vary due to vascular shunting, local blood 
flow changes and global blood pressure. To do so would require sophisticated optical 
detection, and multiple fluorescent tracers: a large particulate tracer that can be imaged during 
flow, a large molecular weight molecule that cannot escape the vessels (or bright organic 
nanodots for example[33]), and a mid-sized molecule that can escape but not to the same 
extent as Na-Fl (353 Da in aqueous solution). Noting that this method is limited in the signal 
to noise in the measured tissue volume, brightness of the tracer will be an important practical 
factor without creating a sharp bolus (i.e. more invasive carotid injection). 10kDa (e.g. a 
chemokine) to 70kDa (e.g. albumin) molecules, if achieving a stable version bright enough to 
observe orders of magnitude lower fluxes, would be feasible sizes to test. Their flux fold-
change would be measurable yet likely markedly different to Na-Fl itself and similar to water. 
The relative comparison may elude to which layers within the wall are disrupted in 
pathologies[34]. This would provide a better understanding of the flow dynamics and size 
selectivity but would still not be able to determine vascular hydrostatic or osmotic pressures. 
The change of ratio between the mid-sized and Na-Fl molecules would allow a more detailed 
understanding of the specific vascular wall layer that is disrupted in DR pathology. 
 
Perspectives  
In summary we highlight a simple, rapid, sensitive method for determining retinal permeability 
that can be used to drastically reduce the number of animals required to determine 






From Fick’s Law: 
𝑃𝑠 =  
𝐽𝑠
𝑆.Δ𝐶
      EQ.1 
 
Where 𝐽𝑠 is the flux of the number of molecules moving into the tissue (𝑁𝑇) 
 
𝐽𝑠 =  
𝑑𝑁𝑇
𝑑𝑡
       EQ.2 
 
S is the exchange area of the capillaries. Δ𝐶 = Difference in concentration between lumen 𝐶𝑉 
and tissue 𝐶𝑇 but if we assume that initially 𝐶𝑇 = 0 and throughout 𝐶𝑇 ≪  𝐶𝑉: 
 
Δ𝐶 = 𝐶𝑉        EQ.3 
 
If L𝑇𝑜𝑡= total length and 𝑟 = mean radius of the vessels within the tissue imaging volume 𝑉1 
(see figure 2A ) the exchange area (S) within 𝑉1 becomes: 
𝑆 = 2π𝑟L𝑇𝑜𝑡     EQ.4 
 
 
𝑉1has a total number of molecules (𝑁𝑉1) being the sum of the molecules in the tissue (𝑁𝑇)  
and capillaries (𝑁𝑐) within it: 
𝑁𝑉1 = 𝑁𝑐  + 𝑁𝑇     EQ.5a 
 












     EQ.6 
 
When substituted in EQ.1 gives: 









                                              EQ.7                                        
 
As all imaging volume 𝑉2 is encompassed by the major vessel, the mean number of 
molecules in the unit volume is 𝐶𝑉. 
𝑁𝑉2
𝑉2
= 𝐶𝑉      EQ.8 
< 𝑁𝑉2 >= 𝐶𝑉                                                      EQ.9    
 
                                   
Where < > denotes the mean over the respective volume. Further the number of molecules 
can be assumed to be directly proportional to fluorescent intensity (𝐼) measured though-out 
(i.e. 𝐼 ∝ 𝛾𝑁) 𝐼 therefore substitutes for 𝛾𝑁 to give: 









                                           EQ.10                                                                 
 
If we assume the capillaries have the same solute concentration as the major vessel then: 
                                                            
𝐼𝑐 =  𝜋𝑟
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Substituting EQ.12 into EQ.10 gives: 
 














   EQ.13               
 
The length of the vessels 𝐿𝑐𝑜𝑛 in the confocal volume 𝑉𝑐𝑜𝑛 (measured subsequent to 








       EQ.14 
 
Substituting for L𝑇𝑜𝑡 in EQ.13 gives: 
 
 















































One of the difficulties with these experiments is finding the real t=0. The tracer is via i.p. 
injection so takes time to reach the vasculature and travel via the heart and lungs to the retinal 
capillaries. Here 𝑃𝑠
𝑡=0 is of the most interest as it fulfils the Δ𝐶 = 𝐶𝑉 axiom. As in figure 2B to 
extrapolate to t=0 the < 𝐼𝑉2 > and < 𝐼𝑉1 > were plotted and t=0 defined as where the linear fit 
for each intercept. This was usually in the order of 20s different to frame timestamp. These 
linear fits were also used to calculate 𝑃𝑠
𝑡=𝑖 adjusting accordingly for the non-zero of the 
intensity intercept either from background or below the detection limit of the camera (this is 
not shown in Figure 2B). From 𝑃𝑠
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Figure 1. In vivo study overview and timeline. Male Brown Norway rats were given a single 
dose of STZ (50mg/kg) i.p. Non-diabetic controls were given an equivalent volume of sterile 
PBS i.p. On day 4 a tail vein blood sample was obtained and blood glucose levels measured. 
Diabetic animals were implanted with an insulin pellet and FFA was carried out on the left eye 
and in the same retinal position on days 0, 7, 14, 21 and 28. On day 28 animals were humanely 
killed by sacrifice and both eyes enucleated. 
  
 
Figure 2. In vivo fundus fluorescein angiography methodology. Na-Fl FFA was performed 
in non- (NDb) and diabetic (Db) Brown Norway rats (250-300g) on days 0, 7, 14, 21 and 28. 
A 3-minute (15 fps) video was captured (A). The mean intensity of Na-Fl in the retinal tissue 
(< 𝐼𝑉1 >) including unresolved capillaries and a main retinal vessel (< 𝐼𝑉2 >) were measured 
every 200 frames for 2 minutes. (B) Example of < 𝐼𝑉1 >  and < 𝐼𝑉2 >  over time used to 
determine initial fluorescein permeability (𝑃𝐹𝑙𝑢𝑜𝑟𝑒𝑠𝑒𝑖𝑛




Figure 3. Retinal vessel dimensions remain unchanged in non-diabetic versus diabetic 
Brown Norway rats. Average retinal vessel length per confocal volume, radius and vascular 
retinal thickness were measured in non-diabetic (NDb) and diabetic (Db) cohorts prior to 
incorporating into the mathematical permeability equation. Eyes were enucleated at sacrifice, 
fixed, hemisected and retinae vessels stained (isolectin B4). (A). Total vessel length per 
confocal volume (B) and radius (C) measurements were calculated from non- and diabetic 
retina. (D) Vascular retinal thickness was measured from the upper to the lower plexus in the 




Figure 4. Retinal Na-Fl permeability 𝑷𝑭𝒍𝒖𝒐𝒓𝒆𝒔𝒆𝒊𝒏
𝒕=𝟎  significantly increases over 28-days in 
diabetic Brown Norway rats and remains unchanged in non-diabetic controls. (A) 
Permeability measurements from 11 diabetic and 14 non-diabetic rats. Bars show 
mean±SEM. Paired one-way ANOVA, with Sidak post-hoc test. (B) Paired results from three 
diabetic and six non-diabetic rats followed for four time points. Statistical analysis using a two-
way ANOVA, with Bonferroni’s post-hoc test. # p<0.05 # # p<0.01, # # # # p<0.0001. **p<0.01 and 
****p<0.0001. # denotes significance between time points, *denotes significance between non-
diabetic vs diabetic per time point. 
 
 
 
